http://www.takeda.com/ IR News http://www.takeda.com/ http://www.takeda.com/favicon.ico icon http://www.takeda.com/press/article_35868.html Deerfield, Ill., (March 4, 2010) – Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. 2010-03-05T08:30:00+09:00 http://www.takeda.com/press/article_35859.html H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) today jointly announced the plans for the additional clinical phase III studies on Lu AA21004 and phase III studies on Lu AA24530 in patients with major depressive disorder (MDD). 2010-03-03T16:30:00+09:00 http://www.takeda.com/press/article_35851.html San Diego, CA – February, 22 and Osaka, Japan – February 23, 2010 – Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target criteria of sustained and robust weight loss. 2010-02-23T08:30:00+09:00 http://www.takeda.com/press/article_35844.html Osaka, Japan (Feb-18) Takeda Pharmaceutical Company Limited “Takeda” today announced that the investigational compound, Hematide™, of which Takeda and Affymax Inc (Palo Alto, Calif) “Affymax” contracted the global license agreement, for the treatment of anemia in chronic renal failure has entered into phase 3 clinical program in Japan. 2010-02-18T15:00:00+09:00 http://www.takeda.com/investor-information/quarterly-results/article_17391.html 2010-02-03T15:00:00+09:00